All News

RegeneCyte's HPC therapy shows promise in treating long COVID symptoms, with 85% of patients reporting fatigue relief.

The FDA prioritizes centanafadine's review for ADHD treatment, offering a novel, once-daily oral option for diverse patient needs.

The FDA approved the first dual-agent eye drops for presbyopia, offering a groundbreaking solution for age-related near vision loss.

Processed plant-based foods, such as breads and cereals, can reduce the risk of diabetes and heart failure when they replace ultraprocessed meats or sugary beverages.

Research data show that weight regain after discontinuation of GLP-1 or GLP-1/GIP agonists is a significant risk.

Discover groundbreaking FDA-approved treatments, including at-home depression therapy, new biosimilars, and culturally relevant pain relief options.

Atebimetinib shows promise in enhancing pancreatic cancer treatment, achieving a 64% survival rate and improving patient quality of life.

Shawn Riser Taylor, PharmD, CPP, CDCES, reflects on a research career shaped by a commitment to patient-driven inquiry and a passion for collaborative, learner-engaged projects.

Multidisciplinary coordination and streamlined workflows enabled rapid patient access to plozasiran after FDA approval at Stony Brook University Hospital.

Key updates include treatment thresholds, dietary recommendations, and management strategies.

Pharmacists play a vital role in identifying and managing primary immunodeficiency diseases, enhancing patient outcomes through immunoglobulin therapy and education.

David Shusterman, MD, reveals how reducing alcohol enhances GLP-1 therapy, improving insulin regulation, kidney health, and overall metabolic outcomes.

Dextromethorphan offers unique mechanisms and potential benefits over traditional antidepressants.

FDA approves a new quadruplet therapy for newly diagnosed multiple myeloma, enhancing treatment options for patients ineligible for stem cell transplant.

Pharmacists play a vital role in supporting multiple sclerosis patients by addressing medication challenges, educating on treatments, and navigating insurance hurdles.

Experts say SMS-based engagement tools can help pharmacists improve medication adherence and reduce hospital readmissions by addressing common patient barriers such as forgetfulness and cost.

Updated guidelines on PA call for expanded screening, treatment, and monitoring, creating opportunities for pharmacists to screen all patients with hypertension.

Explore how pharmacists enhance access to care for multiple sclerosis patients, tackling barriers in diagnosis, treatment, and patient education.

Cardiotoxic signals released from the kidneys may drive cardiovascular risk in patients with chronic kidney disease, opening the door to earlier detection and targeted treatment.

GLP-1 receptor agonist effectiveness and tolerability can be significantly improved through targeted pharmacist counseling on alcohol reduction.

Recent research reveals no link between menopause hormone therapy and dementia risk, urging further studies to clarify its effects on cognitive health.

Effective medication management requires active patient involvement and understanding.

The FDA expands Cerezyme's approval for treating non-CNS symptoms of type 3 Gaucher disease, marking a significant advancement in patient care.

The study found that anxiety and depression in those with Parkinson disease were significantly associated with fatigue severity.

Pharmacists play a crucial role in educating patients with multiple sclerosis about treatment options, adverse effects, and navigating insurance challenges.

FDA's draft guidance on MRD and CR as end points accelerates multiple myeloma therapy approvals, enhancing patient access and transforming oncology practices.

New research reveals how specific gut bacteria in infants may reduce the risk of allergies and asthma, offering potential preventive strategies.